Transgene Biotek share news, announcements and annual reports
BSE: 526139Healthcare ServicesSmall Cap
Transgene Biotek Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993
Last close ₹2.45up ₹0.12 (5.15%)
Share price at the BSE close on 2 Nov 2026. Previous close ₹2.33.
2 Nov: open ₹2.38, high ₹2.57, low ₹2.29
52-week range of traded prices to 2 Nov 2026
₹1.83Low, 4 Feb 2026₹4.19High, 11 Nov 2025
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹19 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 21,872
Transgene Biotek share news and announcements
486 announcements, routine notices left out, newest first. Page 9 of 10.
Aug 2013
19 Aug · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from September 23, 2013 to September 26, 2013 (both days inclusive) ....16 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 15, 2013, inter alia, has decided to convert interest free unsecured loans ....12 Aug · Board Meeting on August 15, 2013
Meeting of the Board of Directors of the Company will be held on August 15, 2013: 1. To take on record the unaudited financial results ....
Jul 2013
Jun 2013
May 2013
Apr 2013
Feb 2013
18 Feb · Limited Review for Dec 31, 2012
15 Feb · Results
Jan 2013
Dec 2012
12 Dec · Management
Following Director has resigned from the Board of Directors of the Company w.e.f. December 02, 2012. - Narayana Murthy Pentyala
Nov 2012
16 Nov · Results
7 Nov · Meeting
Resolution proposed through the notice of postal ballot dated September 20, 2012 for delisting of Equity Shares of the Company from the Indian ....
Oct 2012
17 Oct · Meeting
With reference to the earlier announcement regarding Notice of Postal Ballot wherein the Company had mentioned the date of postal ballot results on November 06, 2012 at 5.30 p.m., Transgene ....
Sep 2012
24 Sep · Updates on Delisting of Securities of the Company
17 Sep · Updates on Delisting of Securities of the Company
With reference to the earlier announcements regarding Delisting of Securities, Transgene Biotek Ltd has now informed BSE that the following Merchant Bankers have been appointed as per the ....10 Sep · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from September 26, 2012 to September 29, 2012 (both days inclusive) ....7 Sep · Updates on Delisting of Equity Shares
4 Sep · Board meeting
Board of Directors of the Company at its meeting held on September 03, 2012, inter alia, has decided to delist the equity shares of the Company ....
Aug 2012
27 Aug · Board Meeting on Sep 03, 2012
Meeting of the Board of Directors of the Company will be held on September 03, 2012: 1. To approve the Directors's Report for the year ....21 Aug · Limited Review for June 30, 2012
16 Aug · Results
Jul 2012
Jun 2012
1 Jun · Results
May 2012
Apr 2012
27 Apr · Transgene Biotek continues its forey westwards
Mar 2012
22 Mar · Change in Compliance Officer
Mr. C Ramakrishna has been appointed as the new Compliance officer of the company with immediate effect.
Feb 2012
23 Feb · Limited Review for Dec 31, 2011
15 Feb · Results
Nov 2011
23 Nov · Sale of Technology by Transgene
15 Nov · Results
Oct 2011
10 Oct · Transgene Biotek commences commercial production of DHA
4 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 03, 2011, has allotted 2,500,000 GDRs underlying 25,000,000 Equity Shares ....3 Oct · Meeting
Members at the 21st Annual General Meeting (AGM) of the Company held on September 30, 2011, inter alia, have passed the following resolutions: ....
Sep 2011
30 Sep · Board meeting
At the meeting of the Board of Directors of the Company held on September 30, 2011, it was decided to open the Issue of GDRs upto USD 20 million ....28 Sep · Board Meeting on Sep 30, 2011
Meeting of the Board of Directors of the Company will be held on September 30, 2011 to decide upon the opening of the Issue of GDRs upto USD 20 million.